Navigation Links
Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
Date:8/14/2014

SOUTH EASTON, Mass., Aug. 14, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced financial results for the three and six-month periods ended June 30, 2014, which included record products and services revenue compared to any prior half-year period. The Company also provided a business update.

Revenue from the sale of products and services was $307,464 for the second quarter of 2014 compared to $196,522 for the same period in 2013, an increase of 56%. Sales of consumables were $48,417 for the three months ended June 30, 2014 compared to $26,034 for the same period in 2013, an increase of 86%. Company operations included no grant revenue for the second quarter of 2014 compared to $161,214 for the comparable period in 2013. Total revenue for the second quarter of 2014 was $307,464 compared to $357,736 for the same period in 2013, a 14% decrease. This decrease was due solely to the loss of $161,214 in grant revenue in the second quarter of 2014, offset almost entirely by a 56% increase in products and services revenue, as stated.

Operating loss for the second quarter of 2014 decreased slightly to $846,757 from $858,026 for the same period in 2013. Although total revenue was down for the three months ended June 30, 2014, attributable solely to the loss in grant revenue, we were able to offset the lost margin through continued increases in products and services revenue and strict control of operating costs.

Revenue from the sale of products and services was $711,611 for the six months ended June 30, 2014 compared to $418,092 for the same period in 2013, a 70% increase. Sales of consumables were $103,029 for the six months ended June 30, 2014 compared to $53,258 for the same period in 2013, a 93% increase. Grant revenue for the six month period ended June 30, 2014 was $0 compared to $310,382 for the same period in 2013. Total revenue for the six months ended June 30, 2014 was $711,611 compared to $728,474 for the same period in 2013, a 2% decrease. This decrease was due solely to the loss of $310,382 in grant revenue in the six month period ended June 30, 2014, offset almost entirely by a 70% increase in products and services revenue, as stated.

Operating loss for the six months ended June 30, 2014 was $1,629,123 compared to $1,583,049 for the same period in 2013. This small increase in operating loss was attributable solely to the 100% loss in grant revenue in the first six months of 2014.

Loss per common share – basic and diluted – was $0.05 for the second quarter of 2014 compared to $0.10 for the same period in 2013.  Loss per common share – basic and diluted – was $0.30 for the six months ended June 30, 2014 compared to $0.22 for the same six-month period of 2013. 

Mr. Richard T. Schumacher, President and CEO of PBI, said: "On June 15th we launched our first-in-class, bench top, high throughput pressure cycling technology ("PCT")-based instrument, the Barozyme HT48, at a major worldwide scientific meeting. The Barozyme HT48 was designed to work with the standardized, high throughput, liquid-handling robotic and analytical systems currently installed in tens of thousands of biological research labs worldwide. With the addition of this important automation compatibility feature, we believe the Barozyme HT48 has the potential to significantly fuel growth and increase revenue for existing and new PCT-based applications and products, and to greatly facilitate future strategic partnership discussions."Mr. Schumacher continued: "We believe the number of PCT-based applications with exciting market potential significantly exceeds the number we can realistically work on.  Consequently, during the second quarter we engaged IssuWorks to begin a review of the possible spin-off of vertical market applications into new, stand-alone businesses. The goal is to have the new business(es) generate a revenue stream for PBI through royalty payments, licensing agreements, equity ownership, etc., while bringing investor and industry awareness to PBI and our powerful PCT Platform. IssuWorks is led by Mr. David Weild, a former vice-Chairman of NASDAQ, former head of global equity transactions at Prudential Securities, and the person many consider to be the 'Father of the JOBS Act'."

Mr. Richard P. Thomley, Chief Financial Officer of PBI, commented: "We are focused on the achievement of a number of important goals during the second half of 2014. Specifically, we believe we can:

  • Continue to increase products and services revenue over 2013 levels.
  • Be in a position to decide on the possible spin-off of selective PCT applications into new, stand-alone businesses designed to generate a revenue stream and favorable visibility for PBI.
  • Secure a strategic marketing and distribution partner for the new Barozyme HT48 high throughput system.
  • Complete the manufacture of 25 Barozyme HT48 and HUB880 instruments and ready them for sale.
  • Develop and implement a successful marketing campaign for the recently released, patent-pending micro-Pestle that has the potential to significantly add to products revenue during the second half of 2014.
  • Continue our measureable progress in developing a sound financial roadmap for future growth."
  • About Pressure BioSciences, Inc. Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

    Earnings CallThe Company will hold an Earnings Conference Call at 4:30 PM EDT on Thursday, August 14, 2014.  To attend this teleconference via telephone: Dial-in: (877) 407-8031 (North America); (201) 689-8031 (International). Verbal Passcode (to be given to the operator): PBI Second Quarter 2014 Financial Conference Call, ID 13589201.

    Forward Looking StatementsThis press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for the quarter ended June 30, 2014 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

    For more information about PBI and this press release, please click on the following website link: 
    http://www.pressurebiosciences.com
    Please visit us on Facebook, LinkedIn, and Twitter.Investor Contacts: Richard T. Schumacher, President & CEO

    (508) 230-1828 (T)Richard P. Thomley, Chief Financial Officer PRESSURE BIOSCIENCES, INC. AND SUBSIDIARYCONDENSED CONSOLIDATED BALANCE SHEETSJune 30,December 31,ASSETS2014(Unaudited)2013(Audited)CURRENT ASSETSCash and cash equivalents

    $9,369$31,417Accounts receivable

    190,725147,635Inventories, net of $50,000 reserve at March 31, 2014 and December 31, 2013

    853,219736,676Prepaid income taxes

    7,3817,381Investor receivable

    200,000-Prepaid expenses and other current assets

    157,60785,573Total current assets

    1,418,3011,008,682Property and  equipment, net

    46,82658,102Intangible assets, net

    12,18236,498TOTAL ASSETS

    $1,480,309$1,103,282LIABILITIES AND STOCKHOLDERS' DEFICITCURRENT LIABILITIESAccounts payable

    $1,162,081$1,102,772Accrued employee compensation

    120,346149,333Accrued professional fees and other

    601,673615,244Deferred revenue

    17,27228,189Promissory note

    -75,000Related party debt

    -25,182Convertible debt, net of debt discount of $100,108 at June 30, 2014 and $311,806 at
    Dec. 31, 2013

    295,056281,796Other debt

    192,62989,989Warrant derivative liability

    321,115344,570Conversion option liability

    41,386356,197Total current liabilities

    2,751,5583,068,272LONG TERM LIABILITIESDeferred revenue

    -2,785TOTAL LIABILITIES

    2,751,5583,071,057STOCKHOLDERS' DEFICITSeries D convertible preferred stock, $.01 par value; 850 shares authorized;

    300 shares issued and outstanding on June 30, 2014 and on Dec. 31, 2013

    33Series G convertible preferred stock, $.01 par value; 240,000 shares authorized;

    86,570 and 145,320 shares issued and outstanding on June 30, 2014 and on Dec. 31,
    2013 respectively

    8651,453Series H convertible preferred stock, $.01 par value; 10,000 shares authorized,

    10,000 shares issued and outstanding on June 30, 2014 and on Dec. 31, 2013

    100100Series J convertible preferred stock, $.01 par value; 6,250 shares authorized;

    4,995 and 5,088 shares  issued and outstanding on June 30, 2014 and on Dec. 31,
    2013 respectively

    5051Series K convertible preferred stock, $.01 par value; 15,000 shares authorized;

    11,463 shares issued and outstanding on June 30, 2014 and 4,000 on Dec. 31, 2013

    11540Common stock, $.01 par value; 50,000,000 shares authorized; 13,796,594 and
    12,024,267 shares issued and outstanding on June 30, 2014 and on Dec. 31, 2013,
    respectively

    137,966120,243Warrants to acquire preferred stock and common stock

    4,920,6334,267,402Additional paid-in capital

    23,341,50419,509,921Accumulated deficit

    (29,672,485)(25,866,988)Total stockholders' deficit

    (1,271,249)(1,967,775)TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

    $1,480,309$1,103,282 

     PRESSURE BIOSCIENCES, INC. AND SUBSIDIARYCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)For the Three Months EndedFor the Six Months  EndedJune 30,June 30,20142013

    20142013Revenue:Products, services, other$307,464$196,522

    $711,611$418,092Grant revenue-161,214

    -310,382Total revenue307,464357,736

    711,611728,474Costs and expenses:Cost of products and services134,45383,829

    312,059188,373Research and development253,238260,408

    484,326506,866Selling and marketing196,074188,392

    367,414382,292General and administrative570,456683,133

    1,176,9351,233,992Total operating costs and expenses1,154,2211,215,762

    2,340,7342,311,523Operating loss(846,757)(858,026)

    (1,629,123)(1,583,049)Other (expense) income:Interest expense (341,649)(63,110)

    (478,313)(72,013)Other expense-(208,709)

    -(208,709)Change in fair value of derivative liabilities585,21963,804

    (255,406)18,359Total other (expense) income 243,570(208,015)

    (733,719)(262,363)Net loss(603,187)(1,066,041)

    (2,362,842)(1,845,410)Accrued dividends on convertible preferred stock(9,606)(39,237)

    (54,593)(71,410)Deemed dividends on convertible preferred stock(107,996)(68,634)

    (1,388,062)(651,182)Net loss applicable to common shareholders$(720,789)$(1,173,912)

    $(3,805,497)$(2,568,002)Net loss per share attributable to common stockholders - basic and diluted

    $(0.05)$(0.10)

    $(0.30)$(0.22)Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation13,567,47211,521,794

    12,848,75111,883,797 


    '/>"/>
    SOURCE Pressure BioSciences, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved


    Related biology technology :

    1. Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports
    2. A Review of Cardiovascular Pressure Sensing and Relevant Performance Specifications to Ensure Data Integrity, a New and Upcoming Webinar Hosted by Xtalks
    3. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
    4. Pressure BioSciences, Inc. to Discuss Third Quarter 2013 Financial Results and Provide a Business Update
    5. Blood Pressure Monitoring Testing Market is Expected to Reach USD 3.7 Billion Globally in 2019: Transparency Market Research
    6. Hazardous, High-Pressure and Explosive Conditions Are No Match for Swiss Jewel Sapphire Windows
    7. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
    8. China Medical Flat Panel Detector Market & Pressure Injector 2013 Research Reports Now Available at ReportsnReports.com
    9. Using pressure to swell pores, not crush them
    10. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
    11. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/11/2016)... ... February 11, 2016 , ... ... focused on the development and manufacture of biopharmaceuticals and therapeutics, announces an ... the 2016 BioProcess International Awards – Recognizing Excellence in the People, Organizations ...
    (Date:2/11/2016)... Feb. 11, 2016  Dovetail Genomics™ LLC today announced ... program for a planned metagenomic genome assembly service. ... metagenomic genome assembly method in a talk on Friday, ... & Technology conference in Orlando, Fla. ... complex datasets is difficult. Using its proprietary ...
    (Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
    (Date:2/11/2016)... WASHINGTON , Feb. 11, 2016   BioInformant ... strategic report, "Stem Cell Research Products, Opportunities, Tools, and ... 2020. ... specialize in the stem cell industry, BioInformant has more ... of the stem cell market, by stem cell type. ...
    Breaking Biology Technology:
    (Date:2/11/2016)... Calif. , Feb. 11, 2016  Vigilant Solutions announces ... LPR data are being used by Lee,s Summit ... including the recent location and arrest of a homicide suspect. ... Summit covers around 65 square miles and is ... Police Department has a single mobile license plate reader ...
    (Date:2/10/2016)... 2016 --> ... iris recognition market report, combined with facial ... widely accepted for border control. Some multimodal ... iris recognition technology in a single device, ... two individual biometrics devices. http://www.rnrmarketresearch.com/global-iris-recognition-market-2016-2020-market-report.html ...
    (Date:2/9/2016)... (NASDAQ: AWRE ), a leading supplier of biometrics software and ... ended December 31, 2015.  --> ... million, an increase of 61% compared to $4.3 million in the ... 2015 was $2.6 million compared to $0.2 million in the fourth ... Higher revenue and operating income in the fourth quarter of ...
    Breaking Biology News(10 mins):